Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.

Gou, Miaomiao; Qian, Niansong; Zhang, Yong; Yan, Huan; Si, Haiyan; Wang, Zhikuan; Dai, Guanghai

Gou, Miaomiao; Qian, Niansong; Zhang, Yong; Yan, Huan; Si, Haiyan; Wang, Zhikuan; Dai, Guanghai.

Afiliação

Gou M; Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Qian N; Sanya Medical Center, Chinese People's Liberation Army General Hospital, Sanya, China.
Zhang Y; Medical Oncology Department, The Second Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Yan H; Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Si H; Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Wang Z; Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Dai G; Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.

Front Oncol ; 12: 851756, 2022.

Article em En | MEDLINE | ID: mdl-35875064